Coming into Year end the IPO market is winding down. This week we have just four IPOs scheduled to raise around $50 million for the week. Cerberus Cyber Sentinel (CISO), Incannex Healthcare (IXHL), Intensity Therapeutics (INTS) and Nuvo Group (NUVO) are expected to debut this week. Cerberus Cyber Sentinel (CISO) Cerberus Cyber Sentinel (CISO) based in Scottsdale, Arizona plans to raise $10 million priced at $5 for a $631 million market cap. The company provides a range of cybersecurity consulting and related services, … Continue reading “US Weekly IPO and SPAC Monitor: Cybersecurity, Cannabidiol and Psychedelics, Cancer and Pregnancy Therapeutics.”
Coming into Year end the IPO market is winding down. This week we have four IPOs scheduled to raise $814 million for the week. IoT solutions developer (IOT) Samsara, CNS biotech Bionomics (BNOX), Fresh Vine Wine (VINE) and Satellite developer Sidus Space (SIDU) are all expected to debut this week. IoT solutions developer Samsara (IOT) Samsara plans to raise $753 million at an $11.6 billion market cap. Samsara is a developer of end-to-end Internet of Things solutions for businesses and provides a cloud-based platform. The … Continue reading “US Weekly IPO and SPAC Monitor : IoT Cloud Solutions Developer Samsara Leads”
Following the Thanksgiving lull the IPO market is expected to pick up with four IPOs scheduled to raise $3.7 billion for the week. Chicago Atlantic Real Estate Finance (REFI) Cloud infrastructure platform HashiCorp (HCP) Austin Gold (AUST) and Buffett-backed Nu Holdings (NU) debut. Cloud infrastructure platform HashiCorp (HCP) Plans to raise $1.1 billion at a $14.0 billion market cap. This VC-backed company provides a suite of solutions that standardize and automate the provisioning, securing, connecting, and running of cloud infrastructure at scale. While it has demonstrated rapid growth and … Continue reading “US Weekly IPO and SPAC Monitor : Buffett-backed Brazil’s Nubank Lead”
Following Thanksgiving week we have just one IPO due. Phase 1-ready biotech Nuvectis Pharma ($NVCT) plans to raise $30 million at a $160 million market cap. Be aware there is still a chance that a handful of SPACs will price during the week. Phase 1-ready biotech Nuvectis Pharma ($NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently … Continue reading “US Weekly IPO and SPAC Monitor : Just One IPO Biotech Nuvectis Pharma”
Amgen today announced it will acquire privately held, clinical stage biotechnology company Teneobio in a deal that includes a $900 million upfront cash payment, plus future contingent milestone payments. Complements $AMGN Antibody Research Capabilities Across Therapeutic Areas.
Pharmaceutical company KemPharm shares have risen after $KMPH received approval for the AZSTARYS NDA an alternative for Adderall and other ADHD treatments. In there fourth quarter earnings they announced a restructured its balance sheet, extinguished its debt and re-listed on The Nasdaq Capital Market. The stock is also heavily shorted.
U.S. Banks reported weaker loan demand for commercial real estate but stronger loan demand for residential real estate The Federal Reserve reported in it’s July 2020 Senior Loan Officer Opinion Survey on Bank Lending Practices.
AstraZeneca on Thursday announced rresults of a clinical trial of its genetically targeted lung cancer drug Tagrisso with an “overwhelming benefit”. $AZN said after two years 89% of the lung cancer patients given Tagrisso following surgery were alive without a recurrence of their tumors.
Co-Diagnostics stock has reversed after surging ahead of it’s first-quarter earnings Thursday and up date of it’s Coronavirus test. $CODX had hit multiple all time highs ahead of the reports.
Allogene Therapeutics on Wednesday released data on the success of it’s off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma blood cancer. The results showing some patients experienced complete remission. The stock $ALLO surged over 50% on the release.